


PHARMACEUTICAL 2017

Rezolute Inc. Rank 277 of 313





PHARMACEUTICAL 2017

Rezolute Inc. Rank 277 of 313

The relative strengths and weaknesses of Rezolute Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Rezolute Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 661% points. The greatest weakness of Rezolute Inc. is the variable Net Income, reducing the Economic Capital Ratio by 455% points.

The company's Economic Capital Ratio, given in the ranking table, is -782%, being 366% points below the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	4,492
Cost of Goods Sold	0
Intangible Assets	52
Liabilities, Current	1,730
Liabilities, Non-Current	400
Other Assets	375
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	16
Property and Equipment	5,985
Research and Development	9,448
Revenues	0
Selling, General and Administrative Expense	5,503

Output Variable	Value in 1000 USD
Assets	10,903
Liabilities	2,131
Expenses	14,951
Stockholders Equity	8,773
Net Income	-14,936
Comprehensive Net Income	-14,936
Economic Capital Ratio	-782%